Comparison of Cantharidin Toxicity in Breast Cancer Cells to Two Common Chemotherapeutics
As part of a larger study synthesizing a more directed form of chemotherapy, we have begun to assess the efficacy of different potential toxins that could be delivered locally rather than systemically. In doing so, we hope to reduce the systemic side effects commonly observed, while maintaining a hi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2014/423059 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555555561930752 |
|---|---|
| author | Katie M. Kern Jennifer R. Schroeder |
| author_facet | Katie M. Kern Jennifer R. Schroeder |
| author_sort | Katie M. Kern |
| collection | DOAJ |
| description | As part of a larger study synthesizing a more directed form of chemotherapy, we have begun to assess the efficacy of different potential toxins that could be delivered locally rather than systemically. In doing so, we hope to reduce the systemic side effects commonly observed, while maintaining a high level of toxicity and eliminating the need for metabolic alterations. In a search for this more efficient method for killing cancerous cells, we have begun studying cantharidin, a toxin used in traditional Chinese medicine, as a potential chemotherapeutic. Using an MTT cell viability assay, the toxicity of cantharidin was compared to both cyclophosphamide and paclitaxel in three different breast cancer cell lines: MCF-7, MDA-MB-231, and SK-BR-3. Increasing the concentration of chemotherapy drugs did decrease cell viability in all cell lines when cantharidin and cyclophosphamide were applied; however differences for paclitaxel were cell-specific. Additionally, cantharidin exhibited the highest decrease in cell viability regardless of cell type, indicating it may be a much more potent and less specific chemotherapeutic. These results will help us move forward in developing a potentially more potent treatment for breast cancer that might eliminate the need for subtype-specific treatments. |
| format | Article |
| id | doaj-art-abe2a3cb0dcd4d5d8e23dfecdf24593f |
| institution | Kabale University |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-abe2a3cb0dcd4d5d8e23dfecdf24593f2025-02-03T05:47:52ZengWileyInternational Journal of Breast Cancer2090-31702090-31892014-01-01201410.1155/2014/423059423059Comparison of Cantharidin Toxicity in Breast Cancer Cells to Two Common ChemotherapeuticsKatie M. Kern0Jennifer R. Schroeder1Department of Biology, Millikin University, Decatur, IL 62522, USADepartment of Biology, Millikin University, Decatur, IL 62522, USAAs part of a larger study synthesizing a more directed form of chemotherapy, we have begun to assess the efficacy of different potential toxins that could be delivered locally rather than systemically. In doing so, we hope to reduce the systemic side effects commonly observed, while maintaining a high level of toxicity and eliminating the need for metabolic alterations. In a search for this more efficient method for killing cancerous cells, we have begun studying cantharidin, a toxin used in traditional Chinese medicine, as a potential chemotherapeutic. Using an MTT cell viability assay, the toxicity of cantharidin was compared to both cyclophosphamide and paclitaxel in three different breast cancer cell lines: MCF-7, MDA-MB-231, and SK-BR-3. Increasing the concentration of chemotherapy drugs did decrease cell viability in all cell lines when cantharidin and cyclophosphamide were applied; however differences for paclitaxel were cell-specific. Additionally, cantharidin exhibited the highest decrease in cell viability regardless of cell type, indicating it may be a much more potent and less specific chemotherapeutic. These results will help us move forward in developing a potentially more potent treatment for breast cancer that might eliminate the need for subtype-specific treatments.http://dx.doi.org/10.1155/2014/423059 |
| spellingShingle | Katie M. Kern Jennifer R. Schroeder Comparison of Cantharidin Toxicity in Breast Cancer Cells to Two Common Chemotherapeutics International Journal of Breast Cancer |
| title | Comparison of Cantharidin Toxicity in Breast Cancer Cells to Two Common Chemotherapeutics |
| title_full | Comparison of Cantharidin Toxicity in Breast Cancer Cells to Two Common Chemotherapeutics |
| title_fullStr | Comparison of Cantharidin Toxicity in Breast Cancer Cells to Two Common Chemotherapeutics |
| title_full_unstemmed | Comparison of Cantharidin Toxicity in Breast Cancer Cells to Two Common Chemotherapeutics |
| title_short | Comparison of Cantharidin Toxicity in Breast Cancer Cells to Two Common Chemotherapeutics |
| title_sort | comparison of cantharidin toxicity in breast cancer cells to two common chemotherapeutics |
| url | http://dx.doi.org/10.1155/2014/423059 |
| work_keys_str_mv | AT katiemkern comparisonofcantharidintoxicityinbreastcancercellstotwocommonchemotherapeutics AT jenniferrschroeder comparisonofcantharidintoxicityinbreastcancercellstotwocommonchemotherapeutics |